We used a polyclonal antiserum directed against calpain II to study the distribution of that enzyme in rat sciatic nerve. Western blot of nerve homogenate showed that the antibody reacted with a single protein band of 80 kDa, corresponding to the catalytic subunit of calpain II. By light microscopy, immunoreactivity appeared predominantly in Schwann cell cytoplasm. By electron microscopy, ealpain II was especially dense along the plasmalemma of Sehwann cells, and was also seen in axoplasm.
Calpains (calcium activated neutral protease, EC 3.4.22.17) are a widely distributed family of cysteine proteases 9. Calpain I is activated by/~M Ca 2+, while calpain II requires mM Ca 2+ for activation 17'1s'3°. Along with their endogenous inhibitor calpastatin 19, both enzymes are found in most tissues including the nervous system 6' 32. Each calpain consists of a catalytic subunit (Mr = 80 kDa) which is distinct for each calpain, and a smaller (M r = 30 kDa) subunit which is common to both calpains 17. The different calpain subunits are the products of distinct genes in man 2°. Many proteins have been identified as potential calpain substrates by in vitro assays 9.
Both calpain 110'13 and calpain I111'12'26 have been isolated from peripheral nerve. In vitro, each of these enzymes is capable of degrading neurofilaments 1°-13'26 in addition to tubulin and microtubule associated proteins I and 115. Calpain II in the central nervous system coisolates with myelin, and is capable of degrading several myelin proteins in vitro 4. The natural substrates of calpain in vivo must be determined by the spatial distribution of the enzyme and its function, dependent on the local control of Ca 2÷ concentration. Previous immunocytochemical studies of calpain distribution in the nervous system have focused on the brain. Calpain I is found in neuronal perikarya in many brain regions 7'8'21'22'29 and has been described in glia by some 21'22, but not by other 7'8 investigators. Similarly, calpain II has been described as predominantly in glia in brain by some 8, but not by other 7 investigators. In the only previous electron microscopic immunocytochemical study of peripheral nerve, an antibody directed against calpains showed immunoreactivity in monkey nerve extracellularly along collagen fibrils and basal lamina, along the axolemma, and on neurofilaments intracellularly 1. In order to better understand the potential role of calpain II in normal nerve function, we used a polyclonal antibody specific for calpain I124 for light and electron microscopic immunocytochemistry of rat sciatic nerve.
The polyclonal antibody generated against rat platelet calpain II (a generous gift of J. Elce) has been previously characterized 24. It has a much higher affinity for rat calpain II than it does for rat calpain I ( In order to determine the antibody's specificity against proteins isolated from nerve, we performed a Western blot 14'31 of protein from rat sciatic nerve homogenized in 5 mM NaCl, 50 mM riffs, pH 7.4. The antibody recognized a single band of M r = 80 kDa (Fig. 1) , corresponding to the catalytic subunit of calpain II, and indicating that the antibody does not cross-react with other proteins (of different molecular weight) in peripheral nerve.
For light microscopic immunocytochemistry, the rats were perfused with 4% paraformaldehyde for 1 h. The nerves were removed, cryoprotected with 2.3 M sucrose overnight, and 1 #m sections cut at -80 °C were placed on gelatin-coated slides. The slides were blocked with 1% ovalbumin in 20 mM glycine and 20 mM Tris-saline (pH 7.6) for 15 min, exposed to the primary antibody (1:5 to 1:100) overnight, followed by goat anti-rabbit antibody conjugated to biotin for 1 h, streptavidin peroxidase (1:100) for 1 h, and developed with diaminobenzidine tetrahydroehloride for 15 rain.
For electron microscopy, ultrathin sections were cut at -120 °C, and the sections on grids exposed to the antiserum (1:5 to 1:20 dilutions) for 2 h, followed by goat anti-rabbit IgG bound to 15 nm colloidal gold as described 15. The grids were stained for 20 rain with uranyl acetate and examined in a JEOL 100S electron microscope. As a control for the immunocytochemical reactions, we performed the same reaction but deleted the primary antibody.
With both the light and the EM immunocytochemistry, the amount of immunoreactivity decreased with progressive dilution of the antibody, but the distribution of immunoreactivity was unchanged.
This antigen-antibody reaction was very sensitive to aldehyde fixation. Post-embedding immunocytochemistry on tissue embedded in LR White, or on etched, osmicated polybed or LR White grids produced no signal. Because of the low fixative content required to preserve antigenicity, the morphology in the cryo-ultrathin section was not optimal, and while the antigen could be localized at the cellular level, fine detail, particularly of the basal lamina and intracellular compartments, was not preserved.
By light microscopy it was apparent that immunoreactivity with this antibody was confined predominantly to Schwann cells (Fig. 2) . Little immunoreactivity was detected within axons and there was no immunoreactivity in the myelin. The control showed no reaction product (Fig. 3) .
By electron microscopy, gold grains indicating immunoreactivity were found diffusely within the cytoplasm of Schwann cells (Fig. 4) , and were especially prominent along the plasmalemma of those cells (Fig. 4C) . In many instances the plasmalemmal immunoreactivity was so dense that the gold particles obscured the extracellular face of the plasma membrane as well as the basal lamina (Fig. 4A, B) . There was also clear immunoreactivity within axons (Fig. 4) , but it appeared to be less intense than the immunoreactivity within Schwann cells. Although occasional gold particles were seen in myelin, there was no consistent immunoreactivity above background in the myelin. Considered with the absence of myelin immunoreactivity by light microscopy, we feel it is most likely that calpain II is not found in significant amounts in compact myelin. These results are important in considering the possible role of calpain II in the peripheral nerve. Calpain II has been implicated in the degradation of neurofilaments that characterizes Wallerian degeneration triggered by the influx of Ca 2÷ into axons, distal to the site of injury 27'32. The intra-axonal localization of calpain II is consistent with this function. Similarly, calpain II can degrade myelin basic protein and myelin proteolipid protein in vitro 4, and is capable of converting myelin associated glycoprotein to a smaller derivative 25. The Schwann cell localization suggests that this mechanism could potentially occur in vivo if local Ca 2+ concentration were elevated, although the absence of myelin immunoreactivity implies that it is not the mechanism for turnover of these proteins within myelin.
The prominent association of calpain II with Schwann cell membranes was of particular interest. In other systems, calpains associate with membrane phospholipids 16 and with integral membrane proteins 23, and it has been suggested that calpain may be activated at the membrane and might mediate membrane lipid and protein interactions 9.
The results of the current study differ from the results of Badalamente et al.1, who reported a predominantly extracellular localization of immunoreactivity in monkey peripheral nerve, using an anti-calpain antibody of undefined isoenzyme specificity. However, our results are in agreement with the results reported by Hamakubo et al. 8 , who found a glial localization of calpain II in brain, and detected immonostaining of axons as well, and are supported by the recent report of calpain II in Schwann cells in vitro 3.
Recent experimental evidence suggests that calpain activity might be important in regulating neurite outgrowth in vitro 28 and in vivo 2. Further studies of calpain distribution in response to nerve injury are currently underway in our laboratory.
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